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Abstract  
Approximately 10% of pregnant women are prescribed antidepressant drugs (ADDs), with 
selective serotonin reuptake inhibitors (SSRIs) the most widely prescribed. SSRIs bind to the 
serotonin transporter (SERT), blocking the reabsorption of serotonin by the presynaptic 
neuron and increasing serotonin levels in the synaptic cleft. The serotonergic system 
regulates a range of brain development processes including neuronal proliferation, 
migration, differentiation and synaptogenesis. Given the presence of SERT in early brain 
development, coupled with the ability of SSRIs to cross the placenta and also enter breast 
milk, concerns have been raised regarding the effects of SSRI exposure on the developing 
foetus and newborns. In this review, we evaluate preclinical and clinical studies that have 
examined the effects of maternal SSRI exposure and the risk for altered neurodevelopment 
and associated behaviours in offspring. While the current body of evidence suggests that 
maternal SSRI treatment may cause perturbations to the neurobiology, behaviour and 
ultimately risk for neurodevelopmental disorders in exposed offspring, conflicting findings 
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do exist and the evidence is not conclusive. However given the increasing incidence of 
depression and number of women prescribed ADDs during pregnancy, further investigation 
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1.1 Introduction. Antidepressant drugs (ADDs) are currently one of the most widely 
prescribed drug classes worldwide, administered to over 10% of the population for the 
treatment of clinical depression and anxiety-related disorders (Moore et al., 2009; Olfson 
and Marcus, 2009). Similarly, 8-10% of pregnant women are prescribed ADDs for the 
treatment of depression (Cooper et al., 2007; Huybrechts et al., 2013). With the overall 
incidence of depression significantly rising over the last several decades, this value may 
continue to increase (Huybrechts et al., 2013; Kessler, 2003). While various classes of ADDs 
exist, selective serotonin reuptake inhibitors (SSRIs) are the most widely prescribed to 
pregnant women (in ~80% of cases) (Huybrechts et al., 2013; Mitchell et al., 2011) and have 
been considered moderately safe for antenatal use (Oberlander et al., 2009). However, 
recent analyses indicate that maternal use of SSRIs, particularly paroxetine, is  associated 
with greater risk of structural neuroteratogenic effects (Reefhuis et al., 2015).  SSRIs, such as 
fluoxetine, sertraline, and citalopram (the most commonly prescribed SSRIs during 
pregnancy (Patil et al., 2011) bind to the serotonin transporter (SERT), blocking the 
reabsorption of serotonin by the presynaptic neuron and increasing serotonin levels in the 
synaptic cleft (Hiemke and Härtter, 2000) (Figure 1). While SSRIs cause acute elevations in 
serotonin concentrations, the antidepressant properties of SSRIs are largely thought to be 
elicited by downstream mechanisms, such as increases in brain derived neurotrophic factor 
(BDNF) and subsequent neurogenesis in the prefrontal cortex (PFC) and hippocampus 
(Martinowich and Lu, 2007). The serotonergic system and other downstream effectors, such 
as BDNF, are also critical for normal neurodevelopment. This raises concerns about 
exposure of the developing foetus and newborns to SSRIs as it has been shown that SSRIs 
administered during pregnancy cross the placenta (Heikkinen et al., 2002) and are excreted 
in breast milk (Hendrick et al., 2001; Kim et al., 2006). This concern is accentuated by studies 
demonstrating associations between abnormal neurodevelopment of the serotonergic 
system and several psychiatric and behavioural disorders, such as Autism Spectrum Disorder 
(ASD) (Hranilovic et al., 2007; Mulder et al., 2004; Schain and Freedman, 1961), Attention-
Deficit Hyperactivity Disorder (ADHD) (Banerjee et al., 2006; Oades et al., 2002; Retz et al., 
2008), anxiety and depression (Caspi et al., 2003; Olivier et al., 2011) and schizophrenia 




1.2 Development of the Serotonergic System 
The serotonergic system plays an important role in early brain development and is critical to 
a range of processes, including neuronal proliferation, migration, differentiation and 
synaptogenesis (Vitalis and Parnavelas, 2003; Whitaker-Azmitia, 2001). Serotonergic 
neurons and receptors appear in the human brain by gestational week 5 (Figure 2); it is one 
of the earliest monoaminergic systems generated during development (Gaspar et al., 2003; 
Lambe et al., 2011; Sundström et al., 1993; Whitaker-Azmitia, 2001). By gestational week 
15, serotonin cell bodies are in their typical organisation in the raphe nuclei, comprised of 
nine distinct cell groups spanning from the medulla oblongata through to the midbrain. The 
caudal division of cell bodies (B1-B5) project serotonergic fibres to the spinal cord, whilst 
the rostral division (B6-B9) provides the major ascending serotonergic fibres to areas 
throughout the forebrain, including the cerebral cortex, hippocampus and basal ganglia, and 
account for 85% of all serotonergic neurons (Glover and Clinton, 2016; Hornung, 2003; Törk, 
1990) (Sodhi and Sanders-Bush, 2004). Serotonin signals through 7 receptor families, 5-HT1-
7, most of which are G-protein coupled, except the ionotropic 5HT3 receptor subtype (Figure 
1). The action of serotonin in the synaptic cleft is terminated by its reuptake by presynaptic 
SERT and subsequent metabolism by monoamine oxidase A (MAO-A) to 5-






Figure 1. Selective serotonin reuptake inhibitors (SSRIs) block the serotonergic transporter 
(SERT), which inhibits the reuptake of serotonin, raising synaptic serotonin concentrations 
that causes prolonged and exaggerated serotonin receptor activation. Serotonin exerts its 
effects via a myriad of g-protein coupled receptors (5HTR1-2, 4-7) and ionotropic receptor 
(5HTR3) subclasses. (a) Serotonin-containing vesicles fuse with the pre-synaptic membrane; 
(b) spilling their contents into the synaptic cleft. (c) SERT removes serotonin from the 
synaptic cleft, modulating the action of serotonin on its receptors. (d) SSRIs bind to SERT and 
inhibit removal of serotonin from the cleft. (e) Activation of presynaptic and (f) (g) 
postsynaptic serotonin receptors exerts varying inhibitory and excitatory effects depending 
on the subclass and location, and regulates synaptic transmission and associated signaling 
cascades. 
 
In the human brain, SERT expression begins in parallel with the emergence of serotonergic 
neurons; SERT positive fibres originating from the raphe nucleus reach the telencephalon at 
gestational week 8, the subplate at gestational week 10 and the cortical plate at gestational 
week 13 (Verney et al., 2002). A similar neurodevelopmental pattern has been 
demonstrated in rodents (Figure 2); SERT expression arises in the serotonergic neurons of 
the raphe nuclei at mid-gestation (embryonic day 13) (Hansson et al., 1998; Rubenstein, 
1998) and serotonin fibers project into the telencephalon by embryonic day 17, passing 
through the septal areas and spreading throughout the cerebral cortex (Sodhi and Sanders-





Figure 2. Schematic of SERT expression in rodents and humans from early gestation to 
adulthood. (a) In rodents, SERT expression follows a similar neurodevelopmental pattern as 
humans, beginning in the raphe neurons at Embryonic Day (ED) 13 then extending to non-
serotonergic neurons at ED17; SERT expression on non-serotonergic neurons ceases in the 
rat brain by postnatal day (PN)12. (b) In humans, SERT expression arises in raphe neurons 
corresponding with the development of the serotonergic system at gestational week (GW) 5, 
and remains through to adulthood. At ~GW12, SERT expression arises in non-serotonergic 
thalamocortical neurons. Whether transient SERT expression occurs in other non-
serotonergic neurons in humans, similar to the rodent brain, remains to be determined. 
Figure adapted from Homberg et al., (2009). 
 
While SERT is largely expressed on serotonergic neurons throughout neurodevelopment and 
maturity, it is also transiently expressed on non-serotonergic neurons. In the rodent brain, 
SERT expression has been shown to appear on non-serotonergic neurons, including 
glutamatergic neurons of thalamocortical pathways, pyramidal neurons in the prefrontal 
cortex and hippocampus (Chen et al., 2016, 2015), and also projection neurons of the 
somatosensory and corticolimbic systems, from approximately embryonic day 17  (Homberg 
et al., 2010; Narboux-Nême et al., 2008). Developmental SERT expression on non-
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serotonergic neurons in the rodent brain ceases in the first two weeks of postnatal life 
(equivalent to birth in humans (Semple et al., 2013), and is localised to serotonergic neurons 
in the mature brain (Narboux-Nême et al., 2008). Likewise in the human brain, an 
anatomically distinct set of non-serotonergic thalamocortical axons (i.e. internal capsule and 
corona radiata) have been observed to transiently express SERT between gestational weeks 
12 and 14 (Verney et al., 2002). Whether this transient expression of SERT on non-
serotonergic corticolimbic and somatosensory neurons also occurs in the human brain has 
not yet been determined.  
The presence of SERT on non-serotonergic neurons and their ability to transiently capture 
serotonin during this early time period alludes to the possible involvement of serotonin in 
key neurodevelopmental processes of non-serotonergic systems. Studies have shown that 
serotonin plays a key role in the development of the neocortex by modulating the migration 
of cortical neurons (Riccio et al., 2011), and the formation of dendritic spines and branches, 
as well as dendritic length, in the hippocampus and cerebral cortex (Sodhi and Sanders-
Bush, 2004; Vitalis and Parnavelas, 2003). During telencephalic development, 
monoaminergic afferents and SERT-expressing thalamocortical axons are in close proximity 
along the internal capsule. These SERT-expressing thalamocortical axons have been shown 
to take up serotonin, and have been implicated in the migration and proliferation of 
developing glutamatergicneurons, potentially through subsequent serotonin release (Edgar 
and Price, 2001; Vitalis and Parnavelas, 2003; Whitworth et al., 2002). In addition, serotonin 
has been shown to modulate the response of developing thalamocortical axons to 
guidancecues, such as Netrin-1, via the serotonin receptor (5HTR1B/1D) (Bonnin et al., 2007). 
The serotonin 5HT1A receptor is highly expressed in the telencephalic proliferative zone in 
early development, where it modulates cell division and proliferation (Hillion et al., 1994; 
Lidow and Rakic, 1995; Varrault et al., 1992; Vitalis and Parnavelas, 2003). Recently, studies 
have shown that serotonin influences the speed and trajectory of migrating GABAergic 
cortical interneurons via activation of 5HT3A receptors (Murthy et al., 2014), and also 
encourages the differentiation of early progenitor cells into glutamatergic neurons in the 
developing cerebral cortex (Lavdas et al., 1997). Taken together, these findings clearly 
implicate the serotonergic system as a key regulator of neurodevelopment, of which 





Considering the critical role of the serotonergic system in neurodevelopment, it is feasible 
that manipulation of the serotonergic system during early development has the potential to 
cause broader disruptions in brain structure and circuitry and lead to associated 
disturbances in brain function and behaviour. Indeed, increased levels of serotonin during 
early development, modelled utilising SERT-knockout mice, was found to cause abnormal 
development of thalamocortical axons and underdevelopment of the somatosensory 
cortical barrels (Gaspar et al., 2003; Persico et al., 2001), as well as increases in anxiety- and 
depressive-like behaviours (Ansorge et al., 2004). Behavioural and biological alterations in 
other serotonergic system knockout models have also been reported with mutants showing 
increased (5HT1A receptor knockout) and decreased (5HT2C and 5A receptor knockout) anxiety 
levels, reductions in GABAA receptor binding and hippocampal neurogenesis (5HT1A receptor 
knockout), as well as increased aggression in MAO-A (the enzyme responsible for 5HT 
degradation) knockout mice (for review see Gaspar et al., 2003). Therefore, altering the 
normal function of the serotonergic system can have broad implications on behavioural and 
biological phenotypes. 
 
2.1 The behavioural and biological effects of maternal SSRI treatment on exposed 
offspring: Evidence from human studies  
Taking into account the significant neurodevelopmental role that the serotonergic system 
plays and the widespread expression of SERT during gestation, manipulation to the 
serotonergic system could have major implications for human neurodevelopment and 
associated disorders. SSRIs administered during pregnancy are transferred across the 
placenta, resulting in prenatal SSRI exposure to the foetus; however, the extent and 
consequences of this exposure on the developing brain are unclear (Hendrick et al., 2001; 
Kim et al., 2006). Studies examining SSRI concentrations in foetal cord blood from treated 
mothers have reported concentrations of at least 50% compared to maternal levels (for 
review see Ewing et al., 2015). Additionally, two enzymes responsible for the metabolism of 
SSRIs in humans, cytochrome P450 2C and 2D6 (CYP2C and CYP2D6), are low or 
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undetectable in the foetal liver but increase progressively during early life (Hines and 
McCarver, 2002; Sadler et al., 2016). Therefore, the foetus and neonate may be particularly 
sensitive to maternal SSRI exposure due to an inability to eliminate drugs through 
metabolism by the liver (Hiemke and Härtter, 2000; Kim et al., 2006). 
Several studies observing birth outcomes of infants exposed to SSRIs in-utero (as early as 
the 1st trimester and throughout pregnancy) have identified an increased risk for preterm 
delivery (Davis et al., 2007; Huang et al., 2014; Maschi et al., 2008; Reis and Källén, 2010), 
low Apgar scores (Casper et al., 2011, 2003; Jensen et al., 2013; Källén, 2004), increased risk 
for low birth weight (Huang et al., 2014; Oberlander et al., 2006; Reis and Källén, 2010), 
frequent intensive care unit admissions (Casper et al., 2011; Galbally et al., 2009), neonatal 
abstinence syndrome (i.e. effects of withdrawal caused by the cessation of SSRI exposure) 
(Levinson-Castiel et al., 2006; Nordeng et al., 2001) and risk for cardiac defects (Källén and 
Otterblad Olausson, 2007; Kornum et al., 2010; Pedersen et al., 2009). Whilst other studies 
report no significant association between prenatal SSRI exposure and cardiovascular 
anomalies (Davis et al., 2007) and pre-term birth (Hendrick et al., 2003), a recent study by 
Reefhuis et al., (2015), suggested that the potential teratogenicity of SSRIs was drug-
specific. Using a Bayesian analysis approach, combining results from independent published 
studies together with data from a multicentre population-based case-control study of birth 
defects, the authors concluded that only fluoxetine and paroxetine were associated with 
increased risk of cardiac defects, while paroxetine alone was associated with an increased 
risk for anencephaly and atrial septal defects (Reefhuis et al., 2015).  
While traditional assessments of drug safety during pregnancy have focused on structural or 
teratogenic defects to exposed offspring, more recent research has focused on the possible 
long-term effects on brain function, behaviour and the development of 
neurodevelopmental disorders. Several studies have examined the effects of maternal 
antidepressant drug treatment on offspring behaviour and risk of neurodevelopmental and 
psychiatric disorders, with a primary focus on ADHD and ASD (Table 1). These studies exhibit 
an apparent division into longitudinal studies that track the development of offspring from 
antidepressant-treated mothers and studies that track the familial history of offspring with 
ADHD and ASD. While the results of these studies are varied, there is evidence to suggest a 
possible association between maternal antidepressant drug use and ASD and/or ADHD and 
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their associated behaviours in exposed offspring. Four out of eight retrospective studies 
reported significant increases in the risk of ASD following prenatal exposure to 
antidepressant (primarily SSRI) treatment (Boukhris et al., 2016; Croen et al., 2011; Gidaya 
et al., 2014; Harrington et al., 2014). Of these studies, two found that maternal SSRI 
treatment was associated with a 2- fold increased risk in the development of ASD in 
offspring, with a three-fold increase in risk observed when exposure occurred in the first 
trimester (Croen et al., 2011; Harrington et al., 2014). Moreover, Croen et al., (2011) found 
no increase in the risk of ASD in offspring of mothers with a history of depression or any 
other health disorder in absence of prenatal SSRI treatment, suggesting that SSRI exposure 
plays an influential role (Croen et al., 2011). Conversely, another study reported that 
maternal history of depression was associated with a greater risk for ASD in offspring, with 
an even greater risk observed when combined with maternal SSRI treatment (Rai et al., 
2013). While these studies are somewhat conflicting, SSRI treatment could be an indicator 
of maternal depressive symptom severity that could also contribute to the greater risk of 
ASD reported in these studies. Interestingly, one study reported that SSRI exposure prior to, 
but not during pregnancy, increased the risk for ASD in offspring (Clements et al., 2015), 
further suggesting that the observed risk for ASD as the result of prenatal SSRI exposure is 
possibly confounded by severity of maternal mental illness. Unfortunately, the measure in 
severity of maternal mental illness in these studies was based on measures such as 
frequency of past hospital admissions, which may be insufficient to truly capture symptom 
severity differences between participants. Nonetheless, Croen et al (2011) did report an 
increase in risk of ASD in offspring exposed to SSRIs in pregnancy, despite taking into 
consideration maternal mental health symptom severity and history (Croen et al., 2011) 
suggesting that symptom severity and history alone may not influence the risks.  
Of the retrospective studies that investigated cases of ADHD, two reported a significantly 
increased risk associated with SSRI exposure and this behavioural disorder (Clements et al., 
2015; Figueroa, 2010). One study reported that SSRI treatment during, but not prior to 
pregnancy was associated with an increased risk for ADHD in offspring (Clements et al., 
2015), suggesting that exposure plays an influential role. In comparison to these findings, 
another study reported an increased risk of ADHD in children of women exposed to SSRIs 
postnatally only, proposing greater emphasis on the influence that maternal mood disorders 
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play during pregnancy; however, the influence of SSRI-exposure through breast milk on 
offspring cannot be ruled out (Figueroa, 2010). Differences in sample sizes, ages and 
methodology may have contributed to the conflicting findings. For example Clements et al., 
(2015) recruited data from cases of ADHD (n= 2,243) in offspring aged 2-19 years, then 
identified those exposed to maternal SSRIs (n= 62), whilst Figueroa et al., (2010) recruited 
data from pregnancies with SSRI exposure (n= 916) and aligned with cases of ADHD (n= 23) 
in offspring aged 0-5 years. 
Collectively, with the exception of Malm et al., (2016), who reported an increased risk for 
depression in adolescent offspring exposed prenatally to SSRIs, the retrospective studies 
largely neglect the assessment of symptoms specific to anxiety and depressive disorders or 
later adolescent ages, and focus instead on ASD, ADHD and the juvenile ages, making it 
difficult to posit the potential longer term effects of maternal SSRI exposure. In addition, 
though the majority of the retrospective studies indicate that maternal SSRI exposure may 
increase the risk for developmental disorders in offspring, it is obvious that the exposure 
period that confers the greatest risk is much deliberated. 
While retrospective studies provide the opportunity for large sample sizes and relative ease 
in data collection, they are limited by their inability to confirm SSRI use/compliance or 
symptom severity of maternal mood disorders during pregnancies. In comparison, despite 
lower samples sizes, longitudinal studies have the added benefit of examining more specific 
subject behaviours and measures of neurodevelopment and associated disorders. Of the ten 
published longitudinal studies, five reported no significant effects of SSRI exposure on 
behavioural parameters, as measured using the Bayley Scales of Infant and Toddler 
Development Instrument (BSID) administered by trained clinicians (Austin et al., 2013; 
Casper et al., 2003; Galbally et al., 2011) and the Child Behaviour Checklist (CBCL), a 
subjective, observational questionnaire completed by subject parents or caregivers (Misri et 
al., 2006; Nulman et al., 2012). The BSID assesses motor, language and cognitive 
development of infants and toddlers aged 0-3.5, whilst the CBCL aims to measure problem 
behaviour in children characterized by internalizing, such as withdrawal and anxiety, and/or 
externalising, such as delinquent or aggressive behaviours (Nøvik, 1999). These studies 
include small sample sizes (n=13-35) that may have limited statistical power to detect any 
associations. Conversely, five studies with larger sample sizes (n=28-5,531) have reported 
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significant associations between maternal SSRI exposure and behavioural disturbances in 
offspring, including autistic traits, anxiety and externalizing behaviours. These studies were 
conducted in cohorts of slightly older children (up to 6 years of age) assessed using the CBCL 
(Hanley et al., 2015; Hermansen et al., 2016; Marroun et al., 2014; Oberlander et al., 2010) 
and BSID (Hanley et al., 2013). The question of whether the conflicting nature of these 
findings is due to the different methodology employed, or other factors such as sample size 
and age of subjects, needs further investigation. Furthermore, it must be acknowledged that 
several longitudinal studies lack effective comparison groups that enable separation of the 
effects of SSRI exposure from the effects of maternal depression (Austin et al., 2013; 
Galbally et al., 2011; Hanley et al., 2013; Misri et al., 2006; Oberlander et al., 2010). In 
addition, the longitudinal studies only examine the juvenile years and as such emotional 
disturbances, such as depression and anxiety, that commonly emerge during adolescent 
years, were not measured (Paus et al., 2008). Therefore, further studies examining later 
time periods would help provide a complete spectrum of potential neurobehavioural 











Table 1: Effects of maternal SSRI exposure on offspring neurodevelopmental disorders: evidence from human studies. 
Study Antidepressants Participants (n) with or 
without symptomology of 


















n = 35 treated/exposed 
+ MDD  
 





Nil significant effects of in-utero SSRI exposure on 
motor, language or cognitive development – assessed 
using the Bayley Scales of Infant and Toddler 
Development instrument (BSID-III). 
 





n = 31 treated/exposed 
+ MDD 
 




Nil significant effects of in-utero SSRI exposure on 
infant neurodevelopmental outcomes measuring motor, 














n = 14 controls untreated 
 -MDD 
internalizing behaviours, based on parental/teacher self-
report using the Child Behaviour Checklist (CBCL) (which 
is designed to screen for psychological disorders and 
associated behaviours, including anxiety, depression, 
social interaction, aggressiveness, attention and 
cognition)(Mazefsky et al., 2011) 
Oberlander et 
al., (2010)  
SSRIs (fluoxetine, paroxetine, 
sertraline, venlafaxine, 
Citalopram) 
n = 33 treated/exposed  
+ MDD 
 
n = 42 controls untreated 
- MDD 
 
3 years Children exposed to SSRIs and maternal depressed 
mood had significantly increased internalizing 
behaviours reported using the CBCL. 
 
Galbally et 




n = 22 treated/exposed  
+ MDD 
 




Children exposed to SSRIs scored lower on motor 
subscales, particularly fine motor and gross motor, using 





SSRIs (Fluoxetine, Paroxetine, 




n = 28 treated/exposed 
+ MDD 
n = 42 controls untreated  
+ MDD 




5-6 years Children exposed to SSRIs had significantly increased 












n = 44 treated/exposed 
+ MDD 
 
n = 66 controls untreated, of 
which n = 10 +MDD 
3 – 6 years Children exposed had significantly increased anxiety 
and internalizing behaviours at 3 and 6 years of age, 
measured using the CBCL. 
 
 
El Marroun et 
al., (2014)  
SSRI 
(paroxetine, fluoxetine, 
sertraline, fluvoxamine and 
citalopram) 
n = 69 treated/exposed  
+ MDD 
 
n = 376 controls untreated 
+ MDD 
 




Prenatal SSRI exposed offspring showed higher risk for 
autistic traits and development of pervasive 
developmental problems compared to those exposed to 
maternal depression only – measured by the CBCL and 
the Social Responsiveness Scale, which focuses 
specifically on dimensions that relate to that of autism 
spectrum disorders, such as social cognition, 
communication and autistic mannerism (Constantino et 
al., 2003). 
 







n = 31 treated/exposed 
+ MDD 
n = 52 controls untreated 
- MDD 
 
10 months Children exposed to SSRIs scored significantly lower on 
gross motor, social-emotional and adaptive behaviour 
using the BSID-III, and after controlling for MDD. 





n = 62 treated/exposed (SSRI) 
+ MDD 
 
n = 62 treated/exposed (SNRI) 
3-6 years IQs of children exposed to venlafaxine and SSRIs were 
significantly lower compared to children of mothers 
with untreated MDD and controls with no history of 








n = 54 controls untreated 
+ MDD 
 




Nil significant differences in cognitive or behavioural 
abnormalities of exposed groups assessed using the 




Hviid et al., 
(2013)  
SSRIs (fluoxetine, sertraline, 
paroxetine, citalopram, 
escitalopram, fluvoxamine) 
n = 6,068 SSRI exposed of 
which 
n= 835 mothers + MDD 
n= 52 offspring + ASD 
 
n = 620,807 control of which 
2647 mothers + MDD 
 
 





SSRI use during pregnancy was not associated with an 





al., (2013)  
 
SSRIs, SNRI, TCA n = 8,833 ADD exposed, of 
which 
n= 1,756 mothers + MDD 
n= 104 + ASD 
 
Of those exposed to ADD; 
n = 7,506 SSRI exposed 
n = 673 SNRI exposed 
n = 642 TCA exposed 
5-9 years Prenatal exposure to SSRIs was not associated with a 





n = 646,782 controls, of which; 
n= 4,324 mothers + MDD 
n= 5,333 + ASD 
Boukhris et 
al., (2016) 
SSRIs, SNRIs, TCA, Monoamine 
Oxidase Inhibitors (MAOI) 
n = 4724 ADD exposed, of 
which; 
n = 46 + ASD 
n = 3290 mothers + MDD 
n = 140,732 controls, of which;  
n = 1008 + ASD 
n = 14,651 mothers + MDD 
0 – 11 
years  
SSRI use was associated with increased risk of ASD in 
offspring, when exposed in the second and/or third 
trimester only (HR 1.87), after accounting for 
confounders.  
Brown et al., 
(2017) 
SSRIs n = 2837 pregnancies ADD 
exposed, of which; 
n = 1176 + Bipolar or MDD 
n = 2364 other 
depressive/anxiety disorder 
 
n = 58 offspring +ASD 
 
n = 33069 pregnancies without 
ADD exposure, of which; 
n = 3175 + Bipolar or MDD 
n = 13589 other 
depressive/anxiety disorder 
 
n = 335 offspring +ASD 
 
4 – 12 
years 
In-utero SSRI exposure was not associated with 







SSRIs, Bupropion, TCA n = 1030 ADD exposed, of 
which; 
n = 28 +ADHD 
 
n = 3532 children of mothers 
+MDD, of which; 
n = 88 +ADHD 
n = 29, 329 children of mothers 
–MDD, of which; 
n = 239 +ADHD 
 
0 – 5 years Significant increase in ADHD in offspring exposed to 
SSRIs postnatally, and not before/during pregnancy (OR 
2.04). 
Significant increase in ADHD in offspring exposed to 
Bupropion during pregnancy, and not before/after (OR 
3.63). 
Brandlistuen 
et al., (2015) 
 
SSRIs, TCA, Other n = 141 ADD exposed, of which; 
n = 90 +MDD 
 
n = 20,039 not exposed, of 
which; 
n = 3831 +MDD 
0-3 years Significant increase in anxiety symptoms in offspring 
exposed to ADDs (r=0.64, p<0.05 regression analysis) 
after adjusting for MDD during pregnancy, MDD history, 








Antidepressants (categorized by 
their 5-HT transporter affinity – 
 





fluvoxamine, venlafaxine.  
 
n = 1,377 ASD, of which 
n= 128 ASD subjects had a 
mother with history of + MDD 
 
n= 4,022 controls, of which 
n= 225 subjects had mother + 
MDD 
 
n = 2,243 ADHD, of which 
n= 184 subjects had mother + 
MDD 
2-19 years ADD exposure during but not prior to pregnancy was 
associated with ADHD (OR 1.69), after adjusting for 
MDD 
ADD use prior to pregnancy but not during was 






Low: nefazodone, bupropion, 
mirtazapine). 
 
n = 5,631 controls, of which 
n= 214 subjects had mother + 
MDD 
Croen et al., 
(2011) 
SSRI, TCA and DAA (dual action 
ADD) 
n = 298 ASD, of which 10 
mothers + MDD 
 
 
n = 1,507 controls, of which 44 
mothers + MDD 
12 to 16 
years 
Two-Fold increased risk of ASD associated with SSRI 
exposure during the year prior to delivery (OR 2.2) 
(including before and during pregnancy), with the 
strongest effect associated with treatment in first 
trimester (OR 3.8).  
 
No increase in risk of ASD in children of mothers with a 
history of mental health treatment and no SSRI use. 







SSRIs (fluoxetine, citalopram, 
paroxetine, sertraline, 
fluvoxamine, escitalopram). 
n = 5,215 ASD, of which; 
n = 76 SSRI exposed  
n= 55 mothers + MDD 
 
n = 52,150 controls 
Of which; 
n = 365 SSRI exposed 
n = 347 mothers + MDD 
8-17 years 
 
In utero exposure to SSRIs increased risk for ASD (OR 
1.8), after adjusting for maternal depression and any 
SSRI indication.  
Harrington et 
al., (2014)  
 
SSRIs (fluoxetine, sertraline, 
paroxetine, citalopram, 
escitalopram) 
n = 492 ASD, of which 122 
mothers + MDD 
 
n = 154 developmental delay, 
of which 40 mothers + MDD 
 
n = 320 controls, of which 67 
2 to 5 
years  
SSRI use associated with greater risk of ASD (OR 2.91), 
with strongest association occurring with first-trimester 
exposure (OR 3.22) and developmental delay in boys (OR 
3.39) (authors report invalid sample size for girls) 
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mothers + MDD 
 
Malm et al., 
(2016)  
SSRIs (fluoxetine, sertraline, 
paroxetine, citalopram, 
escitalopram, fluvoxamine) 
n = 15,729 SSRI exposed, of 
which; 
n = 60 + ASD 
n = 160 + ADHD 
n = 60 + Depression 
n = 65 + Anxiety 
n = 9,651 maternal psychiatric 
disorder, no SSRI, of which; 
n = 79 + ASD 
n = 137 + ADHD 
n = 30 + Depression 
n = 39 + Anxiety 
 
n = 31,394 controls, nil SSRI 
exposure, nil maternal 
psychiatric disorders, of which; 
n = 100 + ASD 
n = 124 + ADHD 
n = 30 + Depression 
n = 62 + Anxiety 
0 – 14 
years 
SSRI exposure was associated with increased rates of 
depression in early adolescence (HR 1.78) but not with 
ASD or ADHD. 
Rai et al., 
(2013)  
 
SSRI, TCA n = 4,429 ASD, of which 44 
mothers + MDD 
 
n = 43,277 control, of which 
272 mothers + MDD 
0-17 years Maternal history of depression was associated with a 
higher risk of ASD in offspring (OR 1.49). Of the 
subsample with available data on ADD exposure, this 
association was limited to women reporting ADD use 
during pregnancy.  
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Abbreviations: ADD = Antidepressant Drug; ADHD = Attention Deficit Hyperactivity Disorder; ASD = Autism Spectrum Disorders; BSID = Bayley Scales of 
Infant and Toddler Development instrument; HR = Hazards Ratio; MDD = Major Depressive Disorder; OR = Odds Ratio; SNRI = Serotonin and Norepinephrine 
Reuptake Inhibitors; SSRI = Selective Serotonin Reuptake Inhibitors; TCA = Tricyclic Antidepressants. 
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While there has been minimal investigation of the neuro-biological consequences of foetal 
SSRI exposure, the limited studies that have been conducted (Bellissima et al., 2015; 
Davidson et al., 2009; Laine et al., 2003; Oberlander et al., 2008; Pawluski et al., 2012, 2009) 
have focused primarily on aspects of the hypothalamic-pituitary-adrenal (HPA) axis and 
neurotransmitter metabolites in cord blood samples, with an absence of studies focusing on 
longer term changes. One study reported significantly decreased serotonin and its main 
metabolite, 5HIAA, by as much as 67% in the cord blood of SSRI exposed infants compared 
to controls (Laine et al., 2003), providing evidence that SSRIs may not necessarily increase 
foetal brain serotonin as it does in the adult brain. However, given that sources of foetal 
serotonin are dynamic and switch progressively during development from exogenous 
(placental) to endogenous (foetal raphe neurons) sources (Bonnin et al., 2011); caution 
needs to be taken when interpreting levels of serotonin in cord blood. Furthermore, another 
study reported a reduction in the dopamine metabolite, homovanillic acid (HVA), and a 
borderline reduction in cord blood noradrenaline (Laine et al., 2003), suggesting that SSRI 
exposure can influence neurotransmission systems beyond serotonin.  The serotonergic 
system is a key regulator of the HPA axis and corticotropin releasing hormone (CRH) release 
is mediated by serotonergic transmission (Heisler et al., 2007b, 2007a). Accordingly, SSRI 
exposed infants have exhibited significantly decreased levels of cortisol in cord blood 
(Davidson et al., 2009) and in salivary samples at three months of age (Oberlander et al., 
2008). 
Recent studies have investigated other potential markers of neurobiological alterations 
caused by maternal SSRI exposure in human samples (Table 2). S100 calcium-binding protein 
β (S100β) is an astroglial-derived neurotrophic factor used as a marker of CNS cellular 
damage when detected at elevated biological concentrations (Kleindienst et al., 2007). One 
study reported significantly increased S100β levels in maternal blood, amniotic fluid, cord 
blood and neonatal peripheral blood throughout pregnancy, at birth and 24hours postnatal 
following maternal treatment with the SSRI paroxetine compared to untreated controls 
(Bellissima et al., 2015). In addition, infants showing major neurological symptoms (i.e. 
hypotonia and seizures) at postnatal day 7 exhibited the highest blood S100β levels 
(Bellissima et al., 2015). Separating these findings in SSRI-treated mothers from the effects 
of innate maternal depression are difficult given that no control group for maternal 
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depression was used (Bellissima et al., 2015), particularly when other studies suggest that 
untreated depressed subjects display higher levels of S100β (Arolt et al., 2003; Grabe et al., 
2001). On the other hand, another study reported decreased S100β levels in cord blood 
following SSRI exposure, even after controlling for maternal mood disorder, but reported 
significantly higher maternal S100β levels in SSRI treated subjects compared with non-
treated (Pawluski et al., 2009). The conflicting findings regarding neonatal S100β levels 
between these two studies may be attributed to the specific SSRIs tested with Pawluski et 
al., (2009) collectively examining a range of SSRIs, whereas Bellissima et al., (2015) included 
data from those mothers treated with paroxetine only. 
Finally, although levels of biological markers taken from blood provide some insight into the 
potential peripheral neurochemical perturbations occurring as the result of SSRI exposure, 
there is no guarantee that these peripheral measures accurately reflect changes in the 
brain. Further studies investigating the long-term effects of SSRI exposure on central 
neurotransmitter systems and their metabolites are required to elucidate the potential for 
these drugs to manipulate the developing brain. This last point is compounded given the 
purported role of the serotonergic system in the development of other systems, including 
glutamate and GABA (refer to section 1.2) and its relationship with neurotrophic markers 




Table  2: Effects of maternal antidepressant administration on biological measures in offspring: Evidence from human studies 
Study Antidepressants Participants (n) Measurements Taken Main Findings  
Bellissima et al. 
(2015) 
SSRI 
(Paroxetine n = 75) 
n = 75 SSRI exposed + MDD or 
other mood disorders 
 
n = 231 controls untreated  
- MDD or other mood disorders 
S100β protein 
concentrations assessed 
in maternal blood, 
amniotic fluid, cord blood 
and neonatal peripheral 
blood.  
 
Samples taken at: 
-16-20, 27-30 and 35-40 
weeks pregnancy 
(maternal blood).  
 
- Birth (amniotic fluid) 
- 24 hours postnatal 
(arterial and venous cord 
blood).  
• Significant increase in S100β levels in 
maternal blood, amniotic fluid, and arterial and 
venous cord blood at all time points. 
 
% Difference in median S100β levels 
16-20 weeks (+233%) 
27-30 weeks (+220%) 
35-40 weeks (+157%) 
Birth (+1425%) 
24 hours (+829%) 
Davidson et al. 
(2009) 
SSRIs  
(paroxetine n = 8,  
fluoxetine n = 7,  
citalopram n = 6) 
n = 21 exposed (details of 
maternal mood disorders 
unknown) 
 
n = 20 control untreated  
- MDD or other mood disorders 
Birth (cord blood) 
- cortisol 
- Thyroid Stimulating 
Hormone (TSH) 






• Significant decrease (-31%) in cord blood 
cortisol levels in the SSRI exposed group. 
• Significant increase (+31%) in cord blood TSH 
levels in SSRI exposed group. 
• Significantly lower (-70%) IGF-I level in infants 
exposed to citalopram only. 
• Significantly elevated (+100%) level of 
placental (IGF-1R) in SSRI exposed group.  



















n = 20 SSRI exposed (n=10 + 
MDD; n=10 + panic disorder) 
 
n = 20 control untreated  
- MDD or other mood disorders 
Birth (cord blood) 
- 5-HT 
- 5-HIAA 





• Significantly decreased cord 5-HT (-67%), 5-
HIAA (-18%) and HVA (-23%), serum prolactin 
(-29%) in the SSRI exposed infants compared 
to control. 
• Borderline significant decrease (-46%; p=0.05) 
cord Noradrenaline in SSRI exposed. 
 
Oberlander et 





n = 31 SSRI exposed (maternal 
mood disorder history not 
stated) 
 
n = 45 control untreated  
- MDD or other mood disorders 
Cortisol collected at 3 
months’ age (saliva) at 
three daily time points, 
before, during, and after 
an information processing 
task. 
 
An additional measure of 
cortisol was taken the 
next day in the 
afternoon/evening. 
• No significant differences in saliva cortisol 
levels between infants during the time points 
associated with the information processing task. 
 
• Evening cortisol was significantly lower (-65%) 
in SSRI exposed infants compared to control.  
 
Pawluski et al. 
(2009) 
SSRIs  
paroxetine n =14,  
fluoxetine n = 6,  
sertraline n = 6,  
citalopram n = 4 
 
n = 36 exposed + MDD or other 
mood disorders 
 
n = 17 controls untreated  
- MDD or other mood disorders 
 
Birth (cord blood) 
- S100β pg/ml 
• Prenatal SSRI exposure significantly lowered (-





Pawluski et al., 
(2012)  
SSRIs 36 Weeks (n) 
n = 47 control untreated - MDD 
or other mood disorders 
 




n = 40 control untreated - MDD 
or other mood disorders 
 
n = 25 exposed + MDD or other 
mood disorders 
Serum at 36 weeks and 
neonates (cord blood) 




Saliva (infants 3month 
old) 
- cortisol 
• Significant increases in serum CBG (+33%) of 
neonates exposed to SSRIs after vaginal 
delivery. 
 
• No significant differences in levels of other 
measured parameters.  
Abbreviations: SSRIs = selective serotonin reuptake inhibitors, IGF-I = insulin-like growth factor, IGF-IR = insulin-like growth factor receptor, TSH = thyroid 
stimulating hormone, 5-HT = 5-hydroxytryptamine, 5-HIAA = 5-hydroxyindoleacetic acid, HVA = homovanillic acid, DHPG = dihydroxyphenylglycine, S100β = 




2.2 Considerations for Human Studies 
Human studies are invaluable to clarify the risks associated with maternal SSRI exposure; yet 
they are confounded by the underlying maternal psychopathology and maternal stress or 
adversities. Furthermore, human studies often omit or report difficulties measuring the 
severity of maternal mood disorders, which may be phenotypically masked due to SSRI 
treatment, and could represent a considerable influence over the observed effects of SSRI 
exposure on offspring. As iterated by Petersen et al., (2014), SSRI use may be a marker of 
severity of underlying mental illness and that may confound the interpretation of these 
clinical findings. Therefore, careful consideration must be given to the interpretation of 
clinical studies and their implications for the broader population, especially when inherent 
difficulties in separating the effects of maternal SSRI exposure from confounding factors, 
such as maternal depression, are often overlooked. 
Maternal mood disorders and adversity themselves are factors associated with a greater risk 
for obstetric complications, impaired pre- and post-natal care and the development of 
psychopathologies in children (Ashman et al., 2002; Davalos et al., 2012; Glover, 2014; 
Hammen and Brennan, 2003; Nulman et al., 2002; O’Connor et al., 2002). Systematic 
reviews have shown that untreated maternal depression is associated with increased 
markers of infant morbidity, including preterm birth, low birth weight, childhood emotional 
and behavioural problems and poor cognitive development (Davalos et al., 2012; Gentile, 
2015; Steer et al., 1992). Studies have also noted neurobehavioural consequences of 
untreated maternal depression or maternal adversity on children, with some showing an 
increased risk for internalizing behaviours (Ashman et al., 2002), decreased cognitive and 
language development (Nulman et al., 2002), developmental delay (Deave et al., 2008) and 
an increased risk for depression, anxiety, ADHD and ASD symptomology (Glover, 2014; 
Hammen and Brennan, 2003; O’Connor et al., 2003, 2002; Rice et al., 2010; Rodriguez and 
Bohlin, 2005; Ronald et al., 2011; Van den Bergh and Marcoen, 2004). Untreated maternal 
depression can also have indirect effects on the offspring through means of unhealthy 
maternal behaviours, for example studies have found a significant association with pregnant 
women suffering from depression and cigarette, alcohol and cocaine use in some people 
(Zuckerman et al., 1989); all well-known to detrimentally affect pregnancy outcomes 
(Cnattingius, 2004; Eyler et al., 1998; Ornoy and Ergaz, 2010). Finally, prenatal depression 
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remains one of the strongest risk factors for postnatal depression (Robertson et al., 2004); a 
disorder linked to developmental problems and increased risk of depression in children 
(Murray et al., 2011; Talge et al., 2007). Severe untreated depression, can also result in 
suicide, which is a major cause of maternal death (Oates, 2003). Therefore, SSRIs continue 
to be critically important to the health and well-being of mothers with depression and 
accordingly, current clinical guidelines from the American Psychiatric Association advise 
against the discontinuation of SSRI use in pregnancy (though switching from paroxetine may 
be advised in some instances), particularly if the chance of psychopathological relapse is 
high (Yonkers et al., 2009). Despite reports of increased risk associated with third trimester 
SSRI exposure and teratogenic effects or neonatal abstinence syndrome, tapering of SSRI 
dosage has also been recommended over discontinuation (Yonkers et al., 2009). Finally, 
although some clinical studies report ~2-3x fold increases in risks for neurodevelopmental 
disorders in offspring exposed to SSRIs (Boukhris et al., 2016; Clements et al., 2015; Croen et 
al., 2011; Gidaya et al., 2014; Harrington et al., 2014), the fact remains that the overall 
incidence/prevalence of these disorders in the population is relatively low (incident rate of 
38.6 per 100,000 and prevalence of 6 per 1000 for ASD (Jensen et al., 2014; Newschaffer et 
al., 2007); and incidence rate of 9.9 per 100,000 and prevalence of 1 per 1000 for ADHD 
(Holden et al., 2013)). The low incidence of behavioural disorders in the general population 
warrants careful consideration in light of the consequences associated with untreated 
maternal depression and the risks this pathology poses for the health and wellbeing of the 
mother and child. Ultimately, this is clearly an area that requires further research with an 
emphasis on discerning the effects of maternal SSRI treatment from maternal 








3.1 The behavioural and biological effects of maternal SSRI treatment on exposed 
offspring: Evidence from animal studies 
Given the inherent difficulties in assessing the effects of developmental SSRI exposure in 
humans, researchers have turned to animal models to gain a deeper understanding of the 
effects of maternal SSRI treatment on exposed offspring. To begin translation of the findings 
from animal models to the clinic, emphasis needs to be placed on the timeline of SSRI-
exposure, and the equivalent neurodevelopmental milestones reached compared to 
humans. In humans, the blood brain barrier is established at 23-32 weeks gestation, whilst 
gliogenesis, synaptogenesis and myelination contribute to the peak brain growth occurring 
at 36-40 weeks gestation (reviewed in Semple et al., (2013)). In rodents, these same 
milestones are reached at PN1 – 3 and PN7 – 10, respectively (Semple et al., 2013). Indeed, 
it has been estimated based on neurodevelopmental comparisons that rodent PN7 is 
equivalent to birth in humans (Clancy et al., 2007). Typically, rodent studies are divided into 
those that deliver SSRIs to dams during gestation (+/- lactation) and others that deliver SSRIs 
directly to pups in the early postnatal period. Despite wide variance in other methodological 
considerations, including drug dosage, administration method and treatment duration, it is 
clear that SSRI exposure in rodent models can alter neurodevelopment in ways that impact 
behavioural characteristics of offspring, including increases in anxiety- and depressive-like 
behaviours, as well as abnormalities in social interaction and exploratory behaviours (Table 
3). With the exception of a few studies (Boulle et al., 2016a, 2016b; Glover et al., 2015; 
Kiryanova et al., 2016; Rayen et al., 2011), the current body of animal literature, does not 
assess the effects of SSRIs in a depression or anxiety model, overshadowing the clinical 
relevance of results. Considering depression and anxiety are associated with altered 
serotonergic development in their own right (Nulman et al., 2012), modelling SSRI exposure 
in a model of depression or anxiety that mimics the underlying serotonergic pathology may 
influence the effects of SSRIs on the serotonergic system. 
Of the 13 studies assessing maternally administered SSRIs, 12 report significant increases in 
anxiety- or depressive-like behaviour and/or deficits in cognition in offspring ranging in age 
from PN8 to PN140 (Table 3). Specifically, seven of these studies demonstrated an increase 
in anxiety-like behaviours following doses ranging from 0.3 – 25mg/kg Fluoxetine (Bairy et 
al., 2006; Boulle et al., 2016b; Lisboa et al., 2007; Noorlander et al., 2008; Olivier et al., 
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2011; Smit-Rigter et al., 2012) and 10mg/kg citalopram (Sprowles et al., 2016), with 
exposure durations from GD0 to PN21. Six studies reported increases in depressive-like 
behaviour measured by the forced swim test, shock escape test and novelty-supressed 
feeding test (Boulle et al., 2016a; Glover et al., 2015; Lisboa et al., 2007; Noorlander et al., 
2008; Rayen et al., 2011; Sprowles et al., 2016). Conversely, six studies found either no 
differences (Glover et al., 2015; Rayen et al., 2011), or decreases in anxiety-like behaviour 
(Francis-Oliveira et al., 2013; Kiryanova et al., 2016; McAllister et al., 2012), and no changes 
(Francis-Oliveira et al., 2013; Olivier et al., 2011) or decreases in depressive-like behaviour 
(Francis-Oliveira et al., 2013; McAllister et al., 2012). In addition, five studies assessed 
cognition, with one noting significant deficits in the passive avoidance test (Bairy et al., 
2006), and another reporting reduced performance in the Morris water maze in SSRI-
exposed offspring; the latter study also reported increased prepulse inhibition (Sprowles et 
al., 2016). On the contrary, other studies reported no changes (Kiryanova et al., 2016; 
McAllister et al., 2012; Olivier et al., 2011), or increases in cognition (spatial memory) in the 
Morris water maze (Bairy et al., 2006). The differences in findings may be attributable to 
differences in drug dosages, subject sex and behavioural test protocols (Table 3). For 
example, one study reported a decrease in ambulation during the OFT in males only, but not 
females, and an increase in immobility time in the forced swim test specifically in females, 
following maternal fluoxetine exposure (Lisboa et al., 2007). Another study reported 
negligible alterations in the behaviour of female rodents exposed to a high dose of 
fluoxetine (McAllister et al., 2012), excluding males from the study. Further studies are 
required to assess the dose effects of SSRI exposure on offspring behaviour of both sexes.   
Studies examining the effects of postnatal SSRI exposure (ranging from PN0 – PN21) on 
offspring behaviour provided the greatest consistency in findings (Table 3). All studies 
reported significant increases in anxiety-like behaviour evident through decreases in 
exploration and/or increases in anxiogenic parameters in the open field test, elevated plus 
maze, light-dark test, novelty-induced hypophagia and novelty-suppressed feeding tests 
(Ansorge et al., 2008, 2004; Karpova et al., 2009; Lee, 2009; Lee and Lee, 2012; Rodriguez-
Porcel et al., 2011; Zheng et al., 2011). Three studies assessed the effects of postnatal 
exposure on offspring depressive-like behaviour. Of those, two reported increases in 
learned helplessness in the shock escape test (Ansorge et al., 2008, 2004) and one reported 
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decreased immobility time in the forced swim test (Karpova et al., 2009). The conflicting 
findings of the three latter studies are likely to be attributable to the different behavioural 
tests used to measure depressive-like behaviour, given that the drug dose and 
administration methods were similar. Indeed, although the forced swim test has been 
validated as an effective measure of antidepressant efficacy and depressive-like behaviour 
in rodents (Slattery and Cryan, 2012), others have suggested that in some cases immobility 
behaviour may resemble a survival mechanism rather than behavioural despair (Nishimura 
et al., 1988). Despite the relative consistency in findings of these studies exposing offspring 
to SSRIs postnatally, translation of the results must be taken with caution. In the clinical 
scenario, SSRIs are transferred via the mother in utero or through breast milk, which has 
been shown to influence the pharmacokinetics of SSRIs (Heikkinen et al., 2002; Velasquez 
and Bonnin, 2016). Therefore, directly exposing offspring to SSRIs postnatally could have an 
exaggerated influence on their behaviour and neurobiology. Nonetheless, these consistent 
findings suggest that the first 14 days of postnatal development in rodents, (third trimester 
in humans (Clancy et al., 2007)), a period marked by peak brain growth (Semple et al., 
2013), represents a time period perhaps more vulnerable to the effects of developmental 
SSRI exposure.  
As previously mentioned, the majority of animal studies assess the effects of developmental 
SSRI exposure in naïve rodents. A limited number assess the effects in models of maternal 
depression (Boulle et al., 2016a, 2016b; Glover et al., 2015; Kiryanova et al., 2016; Rayen et 
al., 2011), which arguably represents the clinical scenario more closely.  Several studies have 
modelled SSRI exposure in dams exposed to environmental stress (as a model of maternal 
depression) through restraint, intense light exposure, confinement or other stressors (Table 
3) (Boulle et al., 2016b, 2016a; Kiryanova et al., 2016; Rayen et al., 2011). Of those studies, 
two reported increased depressive-like behaviour in the forced swim test in SSRI-exposed 
offspring of maternally stressed dams (Boulle et al., 2016a; Rayen et al., 2011). Boulle et al., 
(2016a) reported an increase in immobility in the forced swim test in fluoxetine exposed 
female (but not male) Boulle et al., (2016b)) offspring regardless of maternal stress, whilst 
Rayen et al., (2011) reported increased immobility time in fluoxetine-exposed offspring of 
maternally stressed dams only. Another reported that SSRI-exposed offspring born of dams 
subjected to stress have decreased anxiety-like behaviour compared to SSRI-exposed 
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offspring born of dams naïve to stress (Boulle et al., 2016b). Similarly, Kiryanova et al., 
(2016) reported a reduction in anxiety-like behaviour in male offspring of maternally 
stressed dams exposed to fluoxetine, suggesting that exposure could be beneficial in 
ameliorating the effects of maternal mood on offspring, at least in relation to anxiety-
related behaviour. In comparison to these studies, another study investigated the effects of 
maternal SSRI exposure in selectively bred rats to determine whether innate disturbances in 
emotional behaviour altered susceptibility (or resistance) to the effects of paroxetine 
treatment in offspring (Glover et al., 2015). Using selectively bred Sprague-Dawley rats that 
exhibited decreased anxiety-like behaviour (high responders) or increased anxiety-like 
behaviour (low responders), Glover et al., (2015) showed significantly greater immobility 
times (depressive-like behaviour) in the forced swim test in offspring of paroxetine-treated 
low responder dams, but no other differences in any parameters of the open field test, 
forced swim test and elevated plus maze (Glover et al., 2015). Taken together these findings 
suggest that the effects of developmental SSRI exposure can differ substantially in models of 
maternal adversity and depression (which appears to reflect the findings observed in the 
clinic). Furthermore, animal studies have highlighted an influence of sex on the effects of 










models of maternal 
depression/adversit
y). 
Species, Strain, Drug Dose, Route and 
Duration 
Test and age performed Main Findings: 
(SSRI-exposed offspring compared to control unless 
otherwise stated. Percentages given are approximations) 
Prenatal/maternal exposure  
Bairy et al., (2006)  Species/Strain 
Wistar Rats (n= 16 offspring/group) 
Dose 
Fluoxetine 8 and 12mg/kg 
Route and Duration 




Negative Geotaxis (NG) 
Open Field Test (OFT)  
Rotarod Test (RT) 
Morris Water Maze 
(MWM) 
Elevated Plus Maze (EPM) 
Passive Avoidance (PA) 
 
NG – Flx 8mg/kg increased time to turn 180o at PN10 
(+20%) and PN12 (+53%). 
Flx 12mg/kg decreased time to turn 180o at PN10 (-6%) an 
increased time at PN12 (+44%) 
 
OFT – Increased central, peripheral and total crossings at 
PN18 (Flx 8mg/kg: +320%, +127% and +133%. Flx 
12mg/kg: +136%, +110% and +110%). Decreased central, 
peripheral and total crossings at PN35 (Flx 8mg/kg: -52%, -
15% and -20%. Flx 12mg/kg: -38%, -23% and -25%). No 
differences on PN56. 
 
RT – Increased retention time at PN22 (Flx 12mg/kg: 
+350%) and PN49 (Flx 8 and 12mg/kg: +70%) 
 
MWM – Flx 8mg/kg: Decrease in time to escape at PN24 (-
29%). Flx 12mg/kg decrease time to escape at PN24 and 




PA – Flx 12mg/kg: increase in latency to enter dark 
compartment (+96%) 
EPM – No significant differences 
Summary – SSRI exposure caused a transient delay in 
motor development, favourable effect on cognition and 
learning at higher doses and decreased exploratory 
behaviour at adolescence. 
Glover et al., (2015) 
 
Species/Strain 
Sprague-Dawley Rats (high responders 
and low responders, n= 24 
offspring/group) 
Dose 
Paroxetine 10mg/kg  
Route and Duration 
7 days prior to mating – PN21 Oral 
(dissolved in water) 
PN75 (Adult) 
Locomotor response to 
novelty (LRN) 
EPM 
Forced Swim Test (FST)  
 
FST – exposed low-responders had increased immobility 
compare to vehicle low-responders (+50%). 
LRN and EPM – no differences 
Summary – SSRI exposure exacerbated low-responder’s 
depressive-like behaviour but had no effect on high 
responders. 
 
Lisboa et al., (2007) 
 
Species/Strain 
Swiss Mice (n= 9-17 offspring/group) 
Dose 
Fluoxetine 7.5mg/kg  
Route and Duration 
GD0 – PN21 Gavage  
 
PN30-40 (Adolescence) 




Intruder-resistant test (IRT) 
Hot plate test (HPT) 
Male: 
OFT – Decreased ambulation at PN40 (-16%) 
IRT – Increased latency to first attack (+65%) 
EPM, FST and HPT – no differences 
 
Summary – Males: SSRI exposure induced decreased 
exploratory behaviour at adolescence and decreased 
reactivity/impulsivity in adults.  
Female: 





OFT, EPM and HPT – no differences 
Summary - Females: SSRI exposure increased depressive-
like behaviour at both adolescence and adulthood. 
 
 
Kiryanova et al., 
(2016)  
Species/Strain 
C57BL/6 Mice (n= 16-17 
offspring/group) 
Dose 
Fluoxetine 25mg/kg  
Route and Duration 
GD15 to PN12 Oral (dissolved in 
drinking water) 
Stress (maternal depression model) 
Combination of restricted access to 
food, continuous lighting, cage tilt, 
foreign object in cage, paired housing 
of dams, soiled cage, irregular tones, 





Passive Avoidance Test 
(PAT) 
MWM 
Prepulse Inhibition (PPI) 
IRT 
Social Behaviour (SB) 
EPM – Increase time in open arms in both stressed and 
non-stressed offspring (+96%). 
IRT – Increase in time spent (+223%) engaged in 
aggressive behaviour. 
 
OFT, PAT, MWM and PPI – no difference 
Summary – SSRI exposure caused decreases in anxiety and 
increases in aggression in adulthood, largely independent 
of maternal stress. 
 
Olivier et al., (2011)  Species/Strain 
Wistar Rats (n= 7-16 offspring/group) 
Dose 
Fluoxetine 12mg/kg  
 
Route and Duration 
GD11 – PN1 Gavage 
PN28-35 (Adolescence) 





Conditioned Place Aversion 
(CPA) 
NSF – increased latency to start eating (+110%) 
CPA – increased freezing time in the shock compartment 
(+5%) 
EPMS – decreased time spent in open arms (-45%) 
AdSP – decreased amount of pinning behaviour (-46%) 
OFT, EPM, FST, SPT, ASP and SeB – no difference 
Summary – SSRI exposure caused increases in anxiety-like 
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 EPM – After Stress (EPMS) 
FST 
Sucrose Preference Test 
(SPT) 
Adolescent Social Play 
(ASP) 
Adult Social Play (AdSP) 
 
 
behaviour. No effect on depressive-like behaviour was 
observed. 
Noorlander et al., 
(2008) 
Species/Strain 
C57BL/6 Mice (n= 5-13 
offspring/group) 
Dose 
Fluoxetine 0.3, 0.6 or 0.8mg/kg 
Fluvoxamine 4.2mg/kg 
Route and Duration 
GD8 – 18 Intraperitoneal (IP) 





EPM – increased duration in closed arms at both PN20 
(Flx: +23%, Flv: 14%) 
OFT – decreased distance travelled in the centre arena at 
adulthood (Flx: -56%) 
NSF – increased latency to feed at adulthood (Flx: +240%)  
Summary – SSRI exposure caused increases in anxiety-like 
and depressive-like behaviour  
McAllister et al., 
(2012)  
Species/Strain 
C57BL/6 Mice (n= 16-17 
offspring/group) 
Dose 
Fluoxetine 25mg/kg  
Route and Duration 
GD15 – PN12 Oral (dissolved in 
drinking water) 
PN73 – 83 (adult) 
EPM 
OFT 




Fear Conditioning (FC) 
 
EPM – reduced time spent in closed arms (-21%) 
FST – longer latency to first bout of immobility (+25%) 
OFT, HL, MWM, PPI and FC – no difference 
Summary – SSRI exposure caused decreases in anxiety- 




Boulle et al., (2016a)  
 
Boulle et al., (2016b) 
Species/Strain 
Sprague-Dawley Rats (n= 13-16 
offspring/group) 
Dose 
Fluoxetine 5mg/kg  
Route and Duration 
PN1 – PN21 Osmotic Minipumps 
Stress (maternal depression model) 
Restraint 3x daily under bright light for 




Elevated Zero Maze (EZM) 
FST 
Male: 
OFT – Fluoxetine exposure decreased centre crossing in 
naïve offspring compared to maternally stressed offspring 
(-50%). 
FST – decreased escape driven behaviour in maternally 
stressed offspring regardless of treatment (-12%). 
EZM – no differences 
Summary – In male offspring SSRI exposure in 
combination with maternal stress decreased anxiety-like 
behaviour. 
Female: 
FST – increased immobility (+100%) 
OFT and EZM – no differences 
Summary - In females, SSRI exposure increased 
depressive-like behaviour regardless of maternal stress. 
 
Rayen et al., (2011) 
 
Species/Strain 




Route and Duration 
PN1 – PN21 Osmotic Minipumps 
Stress (maternal depression model) 
Restraint 3x daily under bright light for 
45 minutes from GD15 – GD20. 
PN32 (adolescence)  
OFT 
FST 
FST – Increased immobility in offspring born of maternally 
stressed dams (+150%). 
OFT – no difference 
Summary – SSRI exposure reversed the decrease in 
depressive-like behaviour observed in unexposed 











Fluoxetine 5mg/kg  
Route and Duration 
GD0 – PN21 Gavage 
 




NSF – decreased latency to feed at adolescence (-30%) 
SPT – no difference 
Summary – SSRI exposure caused decreases in anxiety-like 
and depressive like-behaviour in offspring at adolescence. 
 
Smit-Rigter et al., 
(2012)  
Species/Strain 
C57BL/6 Mice (n/group not specified) 
Dose 
Fluoxetine 0.6mg/kg 
Route and Duration 
GD8 – GD18 IP 
 
 
Unknown age of testing 
NSF 
NSF – Increased latency to feed (+66%) 
Summary – SSRI exposure caused increases in anxiety-like 
and depressive like-behaviour in offspring. 
Prenatal/maternal exposure and postnatal/pup exposure 
Sprowles et al., 
(2016b) 
Species/Strain 




Route and Duration (Dams) 
PN60 (adult) 
Straight Channel Swimming 
(SCS) 




MWM – Increased latency to reach platform (+40) 
OFT –decreased centre crossing (-66%, females only) 
MB – increased burying of marbles (+140%) 
PPI – increased response amplitudes (day 1, +280%; day 2, 
+110%) 
FST – decreased latency to first bout of immobility (-100%) 
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GD6 – GD21 2x daily Subcutaneous 
Injection (SC) 
Route and Duration (Offspring) 
PN1 – PN20  2x daily SC 
 
EZM 




SCS, CWM, EZM and SB – no difference 
Summary – SSRI exposed offspring had alterations in 







Lee and Lee (2012) Species/Strain 
Wistar Rats (n= 14-15/group) 
Dose 
Fluoxetine 20mg/kg 
Route and Duration 





OFT – decreased locomotor activity (-23%)  
RT – decreased latency to fall (-44%) 
EPM – no difference 
Summary – SSRI exposed offspring had increased anxiety-
like behaviour, evident through decreased exploratory 
behaviour and impaired motor function. 
 
Ansorge et al., 
(2004)  
Species/Strain 




Route and Duration 




OFT – decreased distance travelled (-40%), reduced total 
ambulatory time (-38%) and vertical activity (-75%) 
EPM – decreased entries into both arms (-30%) 
NSF – increased latency to feed in (+/-) mice only (+130%) 
SE – Increased latency to escape (+150%) 
Summary – SSRI exposure increased anxiety- and 
depressive-like behaviour evident through reduced 
exploratory behaviours, increased latency to feed, and 
increased latency to escape in SERT (+/+) and (+/-) 
40 
 
offspring. Had no effect on SERT (-/-) offspring. 
Ansorge et al., 
(2008) 
Species/Strain 







Route and Duration 








Shock Escape (SE) 
OFT – reduced ambulatory time (-18 to -30%) 
EPM – reduced entries into either arms (-10 to -22%) 
NSF – increased latency to feed (+60 to +45%) 
NIH – increased latency to drink (+83 to +100%) 
SE – increased latency to escape (+25 to +38%) 
Summary – SSRI exposed had increased anxiety- and 
depressive-like behaviour and reduced exploratory 
behaviour. 
Zheng et al., (2011) Species/Strain 
GFP-transgenic mice and wild-type 




Route and Duration 




OFT – decreased distance travelled (-37%) 
Summary – SSRI exposure increased anxiety-like 
behaviour evident through decreased exploratory 
behaviour. 
Karpova et al., 
(2009) 
Species/Strain 




Light-Dark Test (LDT) 
OFT 
FST 
LDT – reduction in rearing (-42%) and increased immobility 
(+11%) 
OFT – reduced rearing (-30%) increased immobility in 
central arena (+42%) 
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Route and Duration 
PN4 – PN21 IP 
 
FST – decreased immobility time (-38%) 
Summary – SSRI-exposed offspring had increased anxiety-
like behaviour but reduced depressive-like behaviour. 
Lee, (2009) Species/Strain 
Wistar Rats (n = 12 – 15/group) 
Dose 
Fluoxetine (10mg/kg) 
Route and Duration 
PN0 – PN6 SC 
PN30 – 35 (adolescence) 
HPT 
Gap-Crossing Test (GCT) 
OFT 
HPT – increased latency to first licking (+110%) 
GCT – decreased crossable gap distance (-36%) 
OFT – decreased total (-20%) and central (-37%) 
ambulation and decreased rearing (-19%) 
Summary – SSRI-exposed offspring exhibited greater pain 
thresholds. Impaired environmental perception (gap-









Route and Duration 
PN8 – PN21 2x daily SC 
PN25 – 39 (adolescence) 
Locomotor Tone (LT) 
Novel Object Approach 
(NOA) 
Juvenile Play (JP) 






LT – increased immobility in response to tone (+180%) 
NOA – reduced time spent investigating the novel object (-
33%) in males 
JP – reduced pinning (-82 to -98%) in males and boxing in 
both male (-71 to -80%) and females (-71%).  
Adult (PN89-184) 
OCP – reduced time spent investigating conspecific subject 
(-58%) 
SB – disrupted mounting behaviour 
Summary – SSRI-exposure increased anxiety-like 
behaviour and impaired social and sexual behaviour in 
offspring.  
Abbreviations: Flx = Fluoxetine; Flv = Fluvoxamine; GD = Gestational Day; PN = Postnatal Day; NG = Negative Geotaxis; OFT = Open Field Test; RT = 
Rotarod Test; MWM = Morris Water Maze; EPM = Elevated Plus Maze; PA = Passive Avoidance Test; LRN = Locomotor Response to Novelty; FST = Forced 
Swim Test; IRT = Intruder Resistant Test; HPT = Hot Plate Test; PAT = Passive Avoidance Test; PPI = Prepulse Inhibition Test; SB = Social Behaviour; NSF = 
Novelty-Suppressed Feeding; CPA = Conditioned Place Aversion; EPMS = Elevated Plus Maze after Stress; SPT = Sucrose Preference Test; ASP = Adolescent 
Social Play; AdSP = Adult Social Play; SeB = Sexual Behaivour; IP = Intraperitoneal; SC = Subcutaneous; HL = Horizontal Ladder; FC = Fear Conditioning; EZM 
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= Elevated Zero Maze; CWM = Cincinnati Water Maze; MB = Marble Burying Test; SCS = Straight Channel Swimming; NIH = Novelty Induced Hypophagia; 
SE = Shock Escape Test; LDT = Light-Dark Test; GCT = Gap-Crossing Test; LT = Locomotor Tone; NOA = Novel Object Approach; JP = Juvenile Play; OCP = 




There is mounting evidence from human and animal studies to suggest neurobehavioural 
alterations in offspring exposed to SSRIs (Tables 1 and 3). Understanding the biological 
foundations of such exposure might help elucidate causative mechanisms underlying 
behavioural alterations and increased risk profiles, and assists in the development of 
appropriate preventative strategies. 
As SSRIs bind to and inhibit SERT, resulting in increased synaptic levels of serotonin, it is 
reasonable to hypothesise that SSRI exposure could lead to altered development of aspects 
of the serotonin system. Several studies have focused on the effect of developmental SSRI 
exposure on the developmental expression of SERT. Specifically, it was reported that SERT 
densities at adolescence (PN28) were significantly increased in the hippocampus, amygdala 
and lateral hypothalamus, decreased in the dorsomedial hypothalamus and substantia 
nigra, and unchanged in the raphe nuclei, of fluoxetine-exposed rodent offspring (Cabrera-
Vera and Battaglia, 1998). The findings indicated brain region specific changes and a 
particular vulnerability of the limbic system (Cabrera-Vera and Battaglia, 1998). 
Interestingly, the same study noted no significant differences in SERT densities between 
exposed and control groups at adulthood (PN70), suggesting that the effects of 
developmental SSRI exposure on SERT are transient in nature and become negligible in later 
life (Cabrera-Vera and Battaglia, 1998). On the contrary another study reported reductions 
in SERT expression in the raphe nucleus that persisted during adolescence (PN20) and 
adulthood (PN90) following exposure to fluoxetine (Noorlander et al., 2008). The same 
study also reported increases in anxiety- and depressive-like behaviour at both PN20 and 
PN90 in offspring exposed to SSRIs in-utero, providing a potential behavioural translation to 
the alterations in SERT expression (Noorlander et al., 2008). Another study assessing 
serotonergic neurons in the raphe nucleus of offspring at PN56 reported marked reductions 
in neuronal number and axonal terminals as a result of SSRI exposure (Silva et al., 2010). The 
contrast in findings in the raphe nucleus between these studies (Cabrera-Vera and Battaglia, 
1998 and Noorlander et al., 2008) may be attributed to the use of different species (rat vs. 
mouse) as well as different drug doses and administration methods (10mg/kg s.c. vs. 
0.8mg/kg i.p. fluoxetine). Interestingly, a high maternal fluoxetine dosage did not produce 
longer lasting changes in SERT expression in the brain of offspring (Cabrera-Vera and 
Battaglia, 1998), which seems paradoxical but may allude to a greater influence of the drug 
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administration method used in these studies. Accordingly, unlike subcutaneous, the 
pharmacokinetics of intraperitoneal injections parallels those administered orally given that 
they are absorbed through the mesenteric vessels and undergo first pass metabolism by the 
liver (Turner et al., 2011), and could result in a greater ratio of active metabolite to parent 
drug.  
Taken together, it may be suggested that SERT expression is altered through a) decreased 
serotoninergic neurons at their origin (raphe nucleus) and hence decreased SERT 
expression, and/or b) alterations in serotonergic afferents to areas including the 
hippocampus and the subsequent altered expression of SERT, or c) the down/up-regulation 
of SERT in response to increased extracellular serotonin. Surprisingly, given the effect of 
SSRIs on the serotonergic system, there have been no studies to-date that have assessed 
the potential alterations to serotonergic receptors or associated signalling. Considering that 
SERT knock-out (KO) rodents have shown reduced 5HT1A receptor binding in the raphe, 
hypothalamus, amygdala and septum (Li et al., 2000), and increased 5HT2A/2C receptor 
binding in the hypothalamus and amygdala (Li et al., 2003), this is clearly an area that 
warrants further investigation. 
Given the neurotrophic role of serotonin during neurodevelopment (Gaspar et al., 2003), 
animal studies have also focused on the effects of developmental SSRI exposure on 
dendritic and neuronal mapping, and markers of neurogenesis, growth and development in 
offspring (Table 4). All studies report significant cellular alterations to some extent with 
varying SSRI exposure duration, dosage and exposure time points (Lee, 2009; Lee and Lee, 
2012; Silva et al., 2010; Smit-Rigter et al., 2012; Swerts et al., 2010; Zheng et al., 2011). 
Exposing embryos to SSRIs during gestation induced significant morphological alterations, 
such as a decrease in neuronal number in the foetal frontal lobe at GD21 following 10mg/kg 
fluoxetine treatment on GD9, 10 and 11 (Swerts et al., 2010). This study provides clear 
evidence of neuronal alterations in exposed offspring; however, examination of any 
potentially permanent alterations from birth to adulthood is required. Another study 
assessed pyramidal neuronal complexity (quantified by measuring dendritic branching and 
length) throughout adolescence to adulthood and reported a significant reduction in 
complexity following administration of 0.6mg/kg/day fluoxetine to dams during GD8 – GD18 
45 
 
(Smit-Rigter et al., 2012). The study provided evidence to suggest alterations caused by SSRI 
exposure persist to adulthood. 
As discussed previously, a limited number of animal studies assess the effects of 
developmental SSRI exposure in clinically relevant models. Several recent studies have 
assessed the effects of SSRI exposure on the neurobiology of offspring using a model of 
maternal adversity by subjecting dams to stress (Boulle et al., 2016b, 2016a; Rayen et al., 
2011). Although varied in methodology, these studies collectively show significant influences 
of SSRI exposure in animal models of stress (Table 4). One study reported a decrease in 
hippocampal neurogenesis and proliferation, and increase in depressive-like behaviour in 
adolescent offspring exposed to maternal stress (Rayen et al., 2011). The same study noted 
that these findings were corrected when the offspring were also exposed to maternal SSRI 
treatment (Rayen et al., 2011), suggesting that SSRI-exposure has the potential to reverse 
the negative effects of maternal depression on offspring, at least in relation to hippocampal 
neurogenesis. It has been widely suggested that the anti-depressive characteristics of SSRIs 
occurs via downstream mechanisms by increasing BDNF expression and subsequent 
neurogenesis (Martinowich and Lu, 2007). In contrast to this notion, one study assessing 
SSRI-exposure during development showed reduced levels of hippocampal BDNF mRNA 
expression in male and female offspring (Boulle et al., 2016a, 2016b). However, when 
examined in a model of maternal adversity, it was shown that the SSRI exposure corrected 
an observable increase in hippocampal BDNF induced by maternal stress in female offspring; 
while in the males, exposure to maternal stress alone or in combination with fluoxetine 
caused no effect (Boulle et al., 2016b). These sex-specific findings highlight the need for a 






Table 4: Effects of maternal antidepressant administration on biological measures in exposed offspring: evidence from animal studies. 





Species, Strain, Drug Dose, Route and Duration Analyses Main Findings 
Prenatal/maternal exposure  
Fornaro et al., (2007)  Species/Strain 





Route and Duration 




Serotonin concentrations in 
Placenta and foetal lungs 
 
Rat foetuses were collected 
via caesarean section on 
GD21 
• Prenatal FLX exposure significantly reduced 
(-38%) placental tissue serotonin content. Did 
not alter lung serotonin content.  
 
Noorlander et al., 
(2008) 
Species/Strain 
Mice (C57BI/6-JIco) (n= 3-6/group) 
 
Dose 
Fluoxetine (0.3, 0.6 or 0.8mg/kg). 
 
Route and Duration 
I.P. injection daily to dams from GD8 to GD18. 
Dorsal raphe nucleus 
examined via 
autoradiography for SERT 
binding (PN20 and PN90) 
 
• Significant decreases at PN20 (-40%) and 
PN90 (-53%) in SERT binding in the raphe 
nucleus after prenatal exposure to FLX 















Route and Duration 
S.C. injection daily to dams from GD13 to GD20 
  
PN28 and PN70 
Cortex, hippocampus, 
septum, amygdala, basal 
ganglia and raphe nucleus – 
autoradiography for SERT 
binding. 
PN28 Following prenatal FLX exposure 
• Significant increases in SERT densities in the 
CA2 and CA3 areas of the hippocampus (+47% 
and +38% respectively). 
 
• Significant increases in SERT densities in 
basolateral (+32%) and medial (+44%) 
amygdaloid nuclei and lateral hypothalamus 
(+21%) of offspring compared to controls.  
 
• Significant reductions in SERT densities in 
dorsomedial hypothalamus (-21%) and 
substantia nigra (-19%) 
 
•Nil significant differences in SERT densities in 
raphe nucleus 
 
PN70 Following prenatal FLX exposure 
• nil significant differences in SERT densities in 





Boulle et al., (2016a) 
 
 
Male offspring study  







Prenatal stress + VEH 
Prenatal stress + FLX 
Control + VEH 






- Quantitative reverse 
transcriptase PCR (qRT-PCR), 
analyses of genes associated 






• Significant decreases in hippocampal BDNF 
exon IV mRNA levels in FLX-exposed offspring 
(-10% non-stressed group; -20% stressed 
group) 
 
• Significant negative correlation (r = -0.33, p 
= 0.02) between hippocampal BDNF exon IV 







Route and Duration 
Osmotic minipumps from PN1 to PN21.  
 
Stress (exposure to confinement and bright 
light for 45min) induced on GD14 to assigned 
dams, occurring 3x daily until end of pregnancy.  
quantification of fragments 
of promoter regions of 
target genes in BDNF/TrKB 
signalling pathway 
Male 
• Significant decreases in BDNF IV (-20%) and 
TrKB (-40%) mRNA expression in the 
hippocampus of FLX-exposed offspring.  
 
• Significant decreases in hippocampal BDNF 
mRNA (-20%) expression of prenatally 
stressed subjects regardless of treatment. 
 
 
Morrison et al., (2004) Species/Strain 





Route and Duration 
Polyvinyl catheters to dam for 8 days, 
commencement ranged from GD118 – 122 ±4-5 
days. 
Foetal blood (sampled daily 







• Significant increase (+115%) in FLX exposed 
foetal plasma cortisol concentrations on 
infusion day(s) 6, 7 and 8. 
 
• Significant increase (+102%) foetal plasma 
ACTH concentrations on infusion day 7 in FLX 
exposed 
 




Prenatal stress + VEH 
Prenatal stress + FLX 
Control + VEH 





Route and Duration 
Immunohistochemistry 
(PN42) 
 - Hippocampus and dentate 
gyrus number of 
proliferating cells and 
immature neurons.  
• FLX exposure significantly reversed the 
decrease in hippocampal cell proliferation 
and hippocampal neurogenesis in prenatally 





Osmotic minipumps to dams from PN1 to PN39. 
 








Route and Duration 




Offspring brains collected to 
determine complexity of 
dendritic tree of layer 2/3 
pyramidal neurons in the 
somatosensory cortex at 
three ages (PN6-9, PN60 and 
PN>365). 
 
Complexity of dendritic tree 
was quantified using the 
Dendritic Complexity Index 
(DCI), which takes into 
consideration dendritic 
branching and dendritic 
length. 
• Significant reduction (~50%) in complexity 
of 2/3 pyramidal neurons of fluoxetine 
exposed animals. Reduction in complexity was 
evident at all life stages (PN6-9, PN60, 
PN>365) 




Fluoxetine or Imipramine (10mg/kg) 
 
Route and Duration 





Dams euthanized GD21, and 
foetuses extracted.  
 
Foetal brains collected and 
analysed via optical 
microscope for visual 
quantification of frontal lobe 







• Significant decreases in the number of 
frontal lobe neurons in FLX (-6%) and IMIP (-






Silva et al., (2010)  Species/Strain  





Route and Duration 
S.C. injections daily to pups from PN1 to PN21 
 
2 months of age (~PN56) 
subject brains collected for 
morphometric analysis of 
5HT neurons in the dorsal 
(DR) and median (MnR) 
raphne nuclei, and 




of serotonergic neurons 
- Perimeter (PER) 
- Maximum, minimum and 
median diameters (Dmax, 
Dmin and Dmed). 
• Significant reduction in neuron number of 
the DR (-26%), and reduced 5HT terminals (-
63%) in the DG of FLX exposed compared to 
vehicles. 
 
• Significant reduction in all morphometric 
parameters of serotonergic neurons. 
DR  
- Perikaryal area (-18%), Dmax (-9.6%), Dmin (-
17%), Perikaryal perimeter (-9.6%). 
 
MnR  
- Perikaryal area (-23%), Dmax (-13%), Dmin (-
10%), Dmed (-14%) Perikaryal perimeter (-
13.5%). 
 
Lee (2009)  Species/Strain  





Route and Duration 
S.C. injections daily to pups from PN0 to PN6. 
PN7 and PN35 
 






• Significant reduction (-51%) in number of 
terminal tips of Thalamocortical afferent 
arbors 
  
• Significant reduction in dendritic field (-
27%), shorter dendritic length (-20%) and 
fewer terminal endings (-20%) in FLX exposed 
compared to vehicle. 
 
• Significant reduction in dendritic spines of 
the 2nd (-43%), 3rd (-42%) and 4th (-40%) 
dendritic orders.  
Lee & Lee (2011)  Species/Strain  





- cerebellum (Purkinje cells) 
Golgi-Cox Impregnation 
•Significant reduction in bifurcation nodes (-
25%), terminals (-25%) and dendritic length (-





Dose and Duration 
S.C. injections daily to pups from PN0 to PN4 
- Striatum (dendritic 
structure) 
- Layer 5 pyramidal neurons 
of primary motor cortex 
Layer 5 pyramidal M1 neurons. 
 
• No significant differences in Purkinje cell 
density and soma size between treatment 
groups 
 
Zheng et al., (2011)  Species/Strain  




Fluoxetine or Fluvoxamine (10mg/kg) 
 
Route and Duration 
I.P. injections daily to pups from PN4 to PN21 
 
Confocal imaging of 
hippocampus neuronal 
development – spinal 
densities of CA1 neurons 
were assessed at PN22 
(adolescence) and PN90 
(adult) stages. 
• Significant reduction (-10%) in spine density 
of basal dendrites at PN22 of SSRI exposed 
groups 
 
• Significant reduction (-16%) in spine density 
of apical dendrites at PN22 of those exposed 
to fluvoxamine 
 
• Significant increase (+15%) in spine density 
of basal dendrites at PN90 of SSRI exposed 
groups 
 
• Significant increase (+13%) in spine density 
of apical dendrites at PN90 of those exposed 
to fluoxetine. 
Abbreviations: FLX = fluoxetine, DA = dopamine, NE = norephinephrine, 5-HT = 5-hydroxytryptamine receptors, DOPAC = 3,4-dihydroxyphenylacetic acid, 
5-HIAA = 5-hydroxyindoleacetic acid, HVA = homovanillic acid, s.c. = subcutaneously, SERT = serotonin transporter, GD = gestational day, PCo2 = partial 
pressure of carbon dioxide, PO2 = partial pressure of oxygen, ACTH = adrenocorticotropic hormone, i.p. = intraperitoneal, CBG = corticosteroid binding 





3.2 Considerations for Animal Studies 
Animal studies, whilst being a step away from the clinic, have begun to address the question 
of whether the reported adverse effects of maternal SSRI treatment on offspring are the 
result of SSRI exposure or a response to innate maternal depression and/or adversity. 
However, a number of limitations and challenges arise when translating preclinical findings 
to the clinical scenario. Firstly, with the exception of studies that model maternal depression 
using environmental stressors, most studies administer SSRIs to healthy dams, which does 
not represent the clinical scenario. Indeed, the very presence of maternal depression, a 
disorder characterized by an underlying serotonergic pathology, could influence the effects 
of maternal SSRI exposure on offspring. One current animal model of depression, the 
Wistar-Kyoto rat (WKY), exhibits serotonergic and behavioural abnormalities similar to 
human depressive disorder (Arango et al., 2001; Lemos et al., 2011; Paré, 1994; Pare and 
Tejani-Butt, 1996; Quan-Bui et al., 1984; Scholl et al., 2010; Sullivan et al., 2006; Zhang et al., 
2005) and could provide an invaluable tool for investigating the effects of SSRI exposure in a 
more clinically relevant setting. For example, the WKY exhibits increased anxiety- and 
depressive-like behaviour, decreased basal serotonin and 5HIAA concentrations, decreased 
SERT density in hippocampal and cortical brain regions, decreased 5HT1a receptor density 
and a reduction in the serotonin rate limiting enzyme, tryptophan hydroxylase; all of which 
have been reported in clinical cases of MDD (Arango et al., 2001; Lemos et al., 2011; Paré, 
1994; Pare and Tejani-Butt, 1996; Quan-Bui et al., 1984; Scholl et al., 2010; Sullivan et al., 
2006; Zhang et al., 2005). Acknowledging that MDD is not characterised by abnormalities in 
the serotonergic system alone, these serotonergic alterations in both clinical cases of MDD 
and the WKY rat could underpin significant differences in response to SSRI exposure 
compared to the response observed in otherwise healthy subjects. Furthermore, the few 
animal studies modelling maternal adversity have shown that maternal SSRI treatment 
differentially affects offspring neurodevelopment and behaviour compared to subjects born 
of dams absent of adversity (Boulle et al., 2016a, 2016b; Kiryanova et al., 2016; Rayen et al., 
2011). Overall, further research utilising appropriate models of depression or adversity are 
required in order to determine the effects of maternal SSRI exposure on offspring in a 
clinically relevant setting.  
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The second limitation to consider when interpreting evidence from animal models is the 
variation in SSRI dosages and treatment duration between studies. Fluoxetine, which 
appears to be the SSRI of choice for animal studies, ranges in dosages from 0.3mg/kg to 
25mg/kg in animal studies whilst in the clinic, daily fluoxetine doses of 20 – 80mg are 
commonly prescribed (Beasley et al., 2000). Further investigation into the dose range that is 
clinically relevant for rodent studies is required. The critical neurodevelopmental time 
period which SSRI exposure confers the greatest changes are also unknown. As such, 
variance in the timing and duration of SSRI exposure during and after gestation remains a 
major difference in methods between rodent studies (Tables 3 and 4). As previously 
discussed animal studies can be divided into those that administer SSRIs maternally, thereby 
indirectly exposing offspring (similar to the clinical scenario), or those that directly 
administer SSRIs to offspring in early life. Neurodevelopmental milestones occurring in 
rodents between PN1 – PN10 are equivalent to those occurring during 23 – 40 weeks 
gestation in humans (Semple et al., 2013). Thus, postnatal exposure in rodents represents 
developmental exposure during the third trimester in humans only and should be 
interpreted as such. It is still unclear from human studies whether there are periods either 
during pregnancy or after that confer greater risks associated with SSRI exposure. Further 
animal studies are required to examine the time-dependent effects of developmental SSRI 
exposure on offspring.  
Finally, animal studies have been useful in the assessment of the molecular effects of SSRI 
exposure on offspring; however, they have largely focused on the serotonergic system and 
neuronal topography, with evidence suggesting that SSRI exposure can produce alterations 
to serotonergic (Raphe) neuronal number, SERT densities and neuronal/dendritic mapping 
in offspring (see Table 4.). Further examination of other neurotransmitter systems 
implicated in the neurobiology and pathology of various developmental neuropsychiatric 
disorders is required. Human studies have suggested an increased risk of ADHD, ASD and 
depression in SSRI-exposed offspring; disorders which are characterized by gross alterations 
in glutamatergic, GABAergic and neurotrophic signalling (Brambilla et al., 2003; Castrén and 
Rantamäki, 2010; Coghlan et al., 2012; Dölen et al., 2007; Duman et al., 2000; Dwivedi et al., 
2003; Hashemi et al., 2016; Hashimoto, 2010; Homberg et al., 2014; Kim et al., 1982; Knable 
et al., 2004; Küçükibrahimoğlu et al., 2009; Lin and Sibille, 2013; Mitani et al., 2006; 
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Sanacora et al., 2012). Indeed, the purported increased risk of inducing developmental 
disorders associated with maternal SSRI exposure could be related to the perturbed 
development of a range of systems, not only serotonin itself. Investigation of other 
neurotransmitter and neurotrophic systems would provide valuable insight into broader 
alterations caused by maternal SSRI exposure and form a basis for future studies. 
 
4. Concluding Remarks  
In conclusion, the current body of evidence suggests that maternal SSRI treatment may 
cause perturbations to the neurobiology, behaviour and ultimately risk for 
neurodevelopmental disorders in exposed offspring. However, conflicting findings do persist 
and the evidence summarised in the current review regarding the safety of SSRI use during 
pregnancy or whilst breast feeding is far from conclusive. Evidence from human studies 
suggest that SSRI exposure during neurodevelopment may be associated with an increased 
risk for neurodevelopmental disorders, such as ADHD and ASD, and mood disorders 
including depression; however, these studies are often confounded by the presence of the 
underlying maternal psychopathology. Difficulties in quantifying or accounting for the 
symptom severity of the maternal psychopathology are often inherent to clinical studies, 
and since SSRI treatment could be phenotypically masking symptoms, the findings warrant 
careful consideration. Furthermore, given that untreated maternal depression and adversity 
themselves are associated with an increased risk for neurodevelopmental disorders; 
maternal SSRI use could in fact be a marker of symptom severity of the underlying mood 
disorder, which itself contributes to the reported risk. Contrary to this notion, preclinical 
studies have reported alterations in behaviour and neurobiology in offspring as the result of 
developmental SSRI-exposure in otherwise healthy animals, suggesting that SSRI exposure 
can cause long lasting perturbations to neurodevelopment, irrespective of the innate 
maternal mood disorder. Although valuable in assessing the effects of developmental SSRI-
exposure in isolation, these studies are limited by the fact that they use healthy or naïve 
animals otherwise free of any underlying psychopathology. In the clinic, SSRI treatment and 
an underlying mood disorder occur in combination and it may be that the underlying mood 
disorder confers a degree of resistance (or exacerbation), or at least influences the effects of 
SSRI-exposure on offspring. The pervading question that remains unanswered is: if SSRI use 
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does increase the risk of neurodevelopmental disorders in offspring, which of the two 
factors - the underlying maternal psychopathology or the SSRI treatment – has a greater 
influence on this risk. Further research utilizing models of depression is required in order to 
clarify the answer to this question in a manner that truly discerns the effects of SSRI-
exposure from the innate maternal mood disorder on offspring neurodevelopment and risk 
for associated disorders. Considering the number of women prescribed ADDs during 
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